晚期卵巢癌预后普遍不佳，当前的治疗策略效果有限。贝伐珠单抗通过抑制血管内皮生长因子A (VEGF-A)活性，有效阻断肿瘤新生血管形成，从而抑制肿瘤的生长。多项研究结果显示，贝伐珠单抗能显著改善卵巢癌患者的预后，并且被国内外多个临床指南推荐用于晚期卵巢癌的治疗。然而，贝伐珠单抗在临床应用中尚未得到广泛接受和规范使用，尤其在应用范围、联合用药策略、耐药性以及药物不良反应等方面存在争议。系统梳理贝伐珠单抗在卵巢癌治疗中的作用机制、用药策略与疗效、安全性以及耐药情况，对于评价其临床治疗价值、探索科学用药具有重要意义。

The prognosis of advanced ovarian cancer（AOC） is generally poor, and the current treatment strategies have limited effectiveness. Bevacizumab effectively inhibits the activity of vascular endothelial growth factor A（VEGF-A） by blocking the formation of new blood vessels in tumors, thereby suppressing tumor growth. Multiple studies have shown that this drug can significantly improve the AOC patients and has been recommended by multiple clinical guidelines for the treatment of AOC. However, Bevacizumab has not yet been widely accepted and standardized in clinical applications, and there are controversies regarding its application scope, combination therapy strategies, drug resistance, and adverse drug reactions. Systematically reviewing the mechanism of action, medication strategies and efficacy, safety, and drug resistance of bevacizumab in the treatment of AOC is of great significance for evaluating its clinical therapeutic value and exploring scientific drug use.

R979.1

安徽省高校自然科学研究重大项目(KJ2019ZD73); 安徽省高校优秀青年骨干人才项目(gxgwfx2019068)